Publication information and format
1. Country/region
2. Sponsor organization
3. Year
4. Number of pages
5. Review date
6. Guideline published in English (Yes/No)
7. Corresponding author (Yes/No)
8. Does the guideline include a flowchart/algorithm?
Identification
1. Male, female, both male and female
2. Individuals who have sustained fragility fractures	a. Age threshold
	b. Fracture types evaluated
	c. Other comments relating to secondary fracture prevention
3. Individuals taking medicines to manage other conditions which are associated with bone loss and/or increased fracture risk:[10]	a. Androgen deprivation therapy
	b. Anticoagulants
	c. Anticonvulsants
	d. Aromatase inhibitors
	e. Calcineurin inhibitors
	f. Glucocorticoids
	g. Medroxyprogesterone acetate
	h. Proton pump inhibitors
	i. Selective serotonin reuptake inhibitors
	j. Thiazolidinediones
	k. Other medicines
4. Conditions associated with bone loss and/or increased fracture risk:[10]	a. Chronic obstructive pulmonary disease
	b. Diabetes
	c. Diseases of malabsorption
	d. Dementia
	e. Rheumatoid arthritis
	f. HIV
	g. Multiple myeloma
	h. Untreated/uncontrolled hyperthyroidism
	i. Other conditions
5. Other risk factors	a. Age 70 years or over
	b. Early menopause
	c. Excessive alcohol intake
	e. Family history
	f. Height loss
	g. Low body mass index/weight
	h. Prolonged immobility
	i. Smoking
	j. Other risk factors
	k. Other comments on identification
Investigation
1. BMD testing, if available
2. Fracture risk calculators	a. FRAX®
	b. Garvan
	c. IOF 1-minute test
	d. KKOS
	e. OSTA
	f. MORES
	g. QFracture
	h. SCORE
3. Vertebral fracture assessment by X-Ray or DXA
4. Falls risk assessment
5. Blood biochemistry	a. Alkaline phosphatase
	b. Calcium
	c. Creatinine
	d. Osteocalcin
	e. uNTX
	g. P1NP
	h. PTH
	i. Vitamin D
	j. Other assays
6. Referral to specialist
Information
1. Information on calcium intake
2. Information relating to sun exposure
3. Information relating to osteoporosis and fracture risk
4. Information relating to exercise
5. Other information
Intervention
1. Which patient groups are indicated for treatment?	a. Hip fracture
	b. Vertebral fracture
	c. Non-hip, non-vertebral fracture
	d. BMD T-Score ≤ –2.5 SD
	e. Osteopenia + FRAX ≥3% Hip or ≥ 20% MOF
	f. Osteopenia + RFs or eligible by OSTA or SCORE
	g. Osteopenia + ≥10 years postmenopausal
	h. FRAX or Garvan ≥3% Hip or ≥ 20% MOF
	i. Eligible by OSTA, MORES or SCORE
	j. QCT <80 mg/cm3
	k. Height loss >4 cm
	l. Androgen deprivation therapy use
	m. Aromatase inhibitor use
	n. Glucocorticoid use
2. Which treatment options are recommended?	a. Bisphosphonates (oral, IV)
	b. Calcium
	c. HRT
	d. Monoclonal antibodies (denosumab, romosozumab)
	e. Parathyroid hormone analogues (abaloparatide, teriparatide)
	f. Selective estrogen receptor modulators (raloxifene. tamoxifen. toremifene)
	g. Vitamin D
	h. Other treatment options
3. Are recommendations made on monitoring treatment?
4. Are recommendations made on treatment duration?
5. Are recommendations made on checking adherence with treatment?
6. Comments on side effects
7. Comments on referral to falls prevention programs
8. Comments relating to other interventions
Integration
1. Are recommendations made to provide the patient with a long-term management plan?
2. Are recommendations made to provide the patient’s primary care provider with a long-term management plan?
Quality
1. Does the guideline advocate audit of care provision against clinical care standards?
2. Does the guideline advocate healthcare providers maintain ongoing professional medical education relating to osteoporosis?